>
Compugen logo

CGEN - Compugen Share Price

$7.79 -0.0  -0.4%

Last Trade - 5:13pm

Sector
Healthcare
Size
Mid Cap
Market Cap £473.9m
Enterprise Value £387.4m
Revenue £1.45m
Position in Universe 3348th / 6927
Bullish
Bearish
Unlock CGEN Revenue
Momentum
Relative Strength (%)
1m -3.34%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -60.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
9.28 0.71 0.000 17.8 0.000 2.00 -26.4%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, CompugenLtd. (USA) revenues was not reported. Net loss increased39% to $9.9M. Higher net loss reflects Research anddevelopment expenses increase of 55% to $7.3M (expense),General and administrative expenses increase of 10% to$2.7M (expense), Marketing and business development expenincrease of 7% to $224K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CGEN
Graphical History

Revenue

CGEN Revenue Unlock CGEN Revenue

Net Income

CGEN Net Income Unlock CGEN Revenue

Normalised EPS

CGEN Normalised EPS Unlock CGEN Revenue

PE Ratio Range

CGEN PE Ratio Range Unlock CGEN Revenue

Dividend Yield Range

CGEN Dividend Yield Range Unlock CGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CGEN EPS Forecasts Unlock CGEN Revenue
Profile Summary

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated February 10, 1993
Public Since August 1, 2000
No. of Shareholders: 38
No. of Employees: 68
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 83,675,856
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CGEN
Upcoming Events for CGEN
Wednesday 28th July, 2021 Estimate
Q2 2021 Compugen Ltd Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 Compugen Ltd Earnings Release
Frequently Asked Questions for Compugen
What is the Compugen share price?

As of 5:13pm, shares in Compugen are trading at $7.79, giving the company a market capitalisation of £473.9m. This share price information is delayed by 15 minutes.

How has the Compugen share price performed this year?

Shares in Compugen are currently trading at $7.79 and the price has moved by -49.29% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Compugen price has moved by -62.79% over the past year.

What are the analyst and broker recommendations for Compugen?

Of the analysts with advisory recommendations for Compugen, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Compugen is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Compugen next release its financial results?

Compugen is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Compugen dividend yield?

Compugen does not currently pay a dividend.

Does Compugen pay a dividend?

Compugen does not currently pay a dividend.

When does Compugen next pay dividends?

Compugen does not currently pay a dividend.

How do I buy Compugen shares?

To buy shares in Compugen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Compugen?

Shares in Compugen are currently trading at $7.79, giving the company a market capitalisation of £473.9m.

Where are Compugen shares listed? Where are Compugen shares listed?

Here are the trading details for Compugen:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CGEN
What kind of share is Compugen?

Based on an overall assessment of its quality, value and momentum, Compugen is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Compugen share price forecast 2021?

Shares in Compugen are currently priced at $7.79. At that level they are trading at 0.172% discount to the analyst consensus target price of 0.00.

Analysts covering Compugen currently have a consensus Earnings Per Share (EPS) forecast of -0.506 for the next financial year.

How can I tell whether the Compugen share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Compugen. Over the past six months, the relative strength of its shares against the market has been -45.98%. At the current price of $7.79, shares in Compugen are trading at -33.02% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Compugen PE Ratio?

We were not able to find PE ratio data for Compugen.

Who are the key directors of Compugen?

Compugen's management team is headed by:

Michal Preminger - DRC
Kinneret Livnat Savitsky - DRC
Anat Cohen-Dayag - PRE
Zurit Levine - VPR
John Hunter - VRD
Ari Krashin - CFO
Paul Sekhri - CHM
Henry Adewoye - OTH
Gilead Halevy - DRC
Jean-Pierre Bizzari - DRC
Eran Perry - DRC
Who are the major shareholders of Compugen?

Here are the top five shareholders of Compugen based on the size of their shareholding:

ARK Investment Management LLC Investment Advisor
Percentage owned: 17.24% (14.4m shares)
ARK Innovation ETF Mutual Fund
Percentage owned: 8.97% (7.51m shares)
Nikko Asset Management Americas, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.56% (7.16m shares)
Nikko AM ARK Disruptive Innovation A USD Mutual Fund
Percentage owned: 6.99% (5.85m shares)
ARK Genomic Revolution ETF Mutual Fund
Percentage owned: 5.17% (4.33m shares)
Similar to CGEN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.